TTK Healthcare: Trading Window Shut from July 1, 2026

Trading window closure: what the company disclosed

TTK Healthcare said it has closed its trading window for designated persons with effect from July 1, 2026, citing compliance requirements under SEBI regulations. The company indicated that the window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This type of closure is typically used to restrict insider trading around the time of financial results and other material disclosures. The company also stated that the board meeting date for considering and approving the unaudited results will be communicated later. The disclosure was addressed to both BSE Limited and the National Stock Exchange of India Limited. The filing date mentioned in the material provided is June 22, 2026. Investors tracking the stock around results season often monitor these timelines because they signal that a results announcement is due, even if the exact board date is not yet known.

Key dates investors are watching

The information provided includes a simple schedule that sets the formal timeline for the trading window mechanism. While the results date itself is not specified, the closure and reopening mechanism is clearly defined. The quarter end date is June 30, 2026, which corresponds to Q1FY27 for many Indian companies. The reopening trigger is tied to the public declaration of results, not the board meeting alone. That distinction matters because the 48-hour period starts only after results are declared to exchanges. The company said the board meeting date will be intimated “in due course,” which means a separate exchange communication is expected.

Board meeting update: still awaited

TTK Healthcare’s disclosure states that the board meeting date for approval of the unaudited financial results for the quarter ending June 30, 2026 will be notified later. It also reiterates that the specific date for the board meeting to consider and approve Q1FY27 unaudited financial results will be intimated in due course. For market participants, this typically means the company is within the results calendar window but has not yet finalised the meeting date, or has not yet communicated it to the exchanges. Until the board meeting date is announced, traders and investors have no official marker for when the results will be approved. The closure itself, however, confirms that the company has moved into a restricted period.

Promoter group disclosure: no encumbrance created

Separately, the material also references a declaration from TTK Prestige. According to the disclosure, TTK Prestige confirmed to stock exchanges that it did not create any encumbrance on its shareholding in TTK Healthcare Limited during the financial year 2025-26. Such statements are tracked because encumbrances, such as pledges, can be relevant to assessing promoter financing risk. Here, the disclosure is straightforward and indicates no encumbrance was created during that year.

Audited FY26 results: board approval and auditor’s view

The provided text also includes a disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015, relating to audited financial results for the fourth quarter and year ended March 31, 2026. The board approved the audited financial results, and the company attached the audited financials along with the auditors’ report issued by PKF Sridhar & Santhanam LLP, Chartered Accountants. The company also confirmed that the auditors’ report carries an unmodified opinion. The material explicitly states that no qualifications, concerns, or issues were raised in the audit opinion. It also notes that the quarter ended March 31, 2026 figures are balancing figures between the audited full year results and previously published limited review figures.

Revenue numbers from audited standalone results (converted to ₹ crore)

The audited standalone table in the material reports revenue from operations in ₹ lakh. Converting these to a single base unit of ₹ crore (1 crore = 100 lakh) yields the following:

Q1 performance snapshot: revenue up, profit down

The material includes quarterly results highlights for the quarter ended June 2025, with comparisons on both QoQ and YoY bases. In that table (stated as “all figures in crores”), total revenue for Jun 25 is ₹226.43 crore, versus ₹207.90 crore in Jun 24, implying an 8.91% year-on-year increase. On a sequential basis, revenue is shown at ₹190.36 crore for Mar 25, implying an 18.95% QoQ increase. However, profitability declined sharply in the same table: net income is ₹13.00 crore in Jun 25 versus ₹31.58 crore in Jun 24, a 58.83% YoY decline. Operating income is listed at ₹0.49 crore in Jun 25 compared with ₹4.86 crore in Jun 24. Diluted normalized EPS is shown at 9.20 for Jun 25 compared with 11.52 for Jun 24.

The text also includes a separate narrative that states revenue increased by 8.91% to ₹2,264.30 crore and net profit declined by 58.82% to ₹130.00 crore, along with EBITDA of ₹27.00 crore and an EBITDA margin of 1.19%. Alongside that, another passage states revenue rose nearly 9% to ₹226 crore, net profit fell to ₹13 crore, and EBITDA fell to ₹2.7 crore with a 1.2% margin. These multiple figures are presented in the supplied material and are not fully consistent in scale, but all point to the same directional trend: revenue growth alongside a sharp decline in profit and operating profitability for the referenced quarter.

Segment information cited in the material

The article text also includes a segment table with revenue and segment result (₹ in crore). As per that table, Consumer Products is the largest revenue contributor at ₹756.30 crore, while Protective Devices shows the highest segment result at ₹63.18 crore. Medical Devices is listed with segment revenue of ₹288.68 crore and segment result of ₹54.43 crore. Other segments cited include Animal Welfare (₹318.84 crore revenue, ₹23.41 crore result), Foods (₹372.43 crore revenue, ₹15.44 crore result), and Others (₹0.92 crore revenue, ₹0.78 crore result). The same material states total assets at ₹13,108.66 crore and total liabilities at ₹2,322.46 crore as of the reporting date.

Stock price references included

The supplied text contains several price points and moves: “920.00,” “929.90 3.95 (0.43%),” and “905.70 -18.80 (-2.03%).” It also states that following an earnings announcement, shares were trading 2.48% lower at ₹1,227, and that the stock is down 13% so far in 2025. Since the dates for each quoted market move are not specified in the material, these should be read as point-in-time references included alongside the disclosures and results summary.

Company contact details listed in the filing material

The material includes the company’s registered address and contact details: No 6, Cathedral Road, Chennai (Madras), Tamil Nadu 600086. It also lists telephone number 044-28116106, fax 044-28116387, email info@ttkhealthcare.com, and website http://www.ttkhealthcare.com. These details typically appear in corporate filings and exchange communications.

What to track next

The next formal update investors are likely to watch for is the intimation of the board meeting date for Q1FY27 (quarter ended June 30, 2026). The trading window will reopen only 48 hours after the unaudited results are declared. Separately, the audited FY26 disclosures and the unmodified audit opinion establish the status of the company’s annual reporting as communicated. Any further clarity on quarterly performance will depend on the upcoming Q1FY27 results announcement and the detailed financial statement disclosures made to the exchanges.